Ocular hypotensive and vasodilative effects of two β-adrenergic blockers with intrinsic sympathomimetic activity

Current Eye Research

Volumn 17, Issue 7, 1998, Pages 700-707

  Hong, Show Jen ^a   Wu, Kwou Yeung ^a   Chen, Ing Jun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

(beta) adrenergic blockers; Calcium; cAMP; Eugenolol; Intraocular pressure; Rabbit; Sympathomimesis; Vaninolol; Vasodilator

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ION; CYCLIC AMP; EUGENOLOL; FURA 2 ACETOXYMETHYL ESTER; GLUCOSE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VANINOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CILIARY BODY; CONTROLLED STUDY; DRUG EFFECT; EMBRYO; EYE BLOOD FLOW; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; INTRINSIC SYMPATHOMIMETIC ACTIVITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RADIOIMMUNOASSAY; RAT; SPECTROFLUOROMETRY; SWINE; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AORTA; BUTANONES; CELL LINE; CILIARY BODY; CYCLIC AMP; EUGENOL; EYE; GLUCOSE; INJECTIONS, INTRAVENOUS; INTRAOCULAR PRESSURE; ISOPROTERENOL; MUSCLE, SMOOTH, VASCULAR; OCULAR HYPERTENSION; PROPANOLAMINES; RABBITS; RATS; REGIONAL BLOOD FLOW; SWINE; SYMPATHOMIMETICS; VASODILATOR AGENTS;

EID: 0031819901     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1076/ceyr.17.7.700.5167     Document Type: Article

References (58)

1. James CB, Smith SE. Pulsatile ocular blood flow in patients with low tension glaucoma. Br J Ophthalmol. 1991; 75:466-470.
2. Critini G. Common pathological basis for the nervous ocular symptoms in chronic glaucoma. Br J Ophthalmol. 1950;35:11-20.
3. Francois J, Neetens A. Vascularity of the eye and the optic nerve in glaucoma. Arch Ophthalmol. 1964;71:219-225.
4. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. Br J Ophthalmol. 1967;51:222-226.
5. Bonomi I, Steindler P. Effect of pindolol on intraocular pressure. Br J Ophthalmol. 1975;9:301-303.
6. Vareilles P, Silverstone D, Plazonner B, Le Douarec JC, Sears ML, Stone CA. Comparison of timolol and other adrenergic agents on intraocular pressure in the rabbit. Invest Ophthalmol Vis Sci. 1977;16:987-1014.
7. Wettrell K. Beta-adrenoceptor antagonism and intraocular pressure: a clinical study on propranolol, practolol and atenolol. Acta Ophthalmol. 1977;55:1-54.
8. Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol: a new drug for management of chronic simple glaucoma. Arch Ophthalmol. 1978;96:1003-1008.
9. Liu JH, Bartels SP, Neufeld AH. Effects of L- and D-timolol on cyclic AMP synthesis and intraocular pressure in water-loaded, albino and pigmented rabbits. Invest Ophthalmol Vis Sci. 1983;24:1276-1282.
10. Kim JW, Smith PH. Timolol-induced bradycardia. Anesth Analg. 1980;59:301-303.
11. Guzman CA. Exacerbation of bronchorrhea induced by topical timolol. Am Rev Respir Dis. 1980;121:899-900.
12. McLaughlin MA, Chiou GCY. Synopsis of recent developments in antiglaucoma drugs. J Ocular Pharmacol. 1985;1:101-122.
13. Chiou GCY, Zhao F, Shen ZF, Li BHP. Effects of D-timolol and L-timolol on ocular blood flow and intraocular pressure. J Ocular Pharmacol. 1990;6:23-30.
14. Chiou GCY, Chen YJ. Effects of D- and L-isomers of timolol on retinal and choroid blood flow in ocular hypertensive rabbit eyes. J Ocular Pharmacol. 1992;8:183-190.
15. Chiou GCY, Yan HY. Effects of antiglaucoma drugs on the blood flow in rabbit eyes. Ophthalmic Res. 1986;18:265-269.
16. Martin XD, Rabineau PA. Vasoconstrictive effect of topical timolol on human retinal arteries. Graefe's Arch Clin Exp Ophthalmol. 1989;227:526-530.
17. Wu BN, Yang CR, Yang IM, Chen IJ. A new β-adrenoceptor blocking agent derived from dehydrozingerone. Gen Pharmacol. 1994;25:651-659.
18. 1-adrenoceptor antagonist derived from vanillin. Biochem Pharmacol. 1994;48:101-109.
19. Wu BN, Ho WC, Chiang LC, Chen IJ. Zingeronolol: a newly developed β-adrenergic blocking agent derived from zingerone, a pungent principle of ginger. Asia Pacific J Pharmacol. 1996;11:5-12.
20. Chen IJ, Yen JL, Lo YC, Sheu SH, Lin YT. Capsinolol: the first β-adrenoceptor blocker with an associated calcitonim gene-related peptide releasing activity in the heart. Br J Pharmacol. 1996;119:7-14.
21. Sheu MM, Wu BN, Ho WC. Vanidilol: a vanilloid-type vasorelaxant and ocular hypotensive beta-adrenoceptor blocker with partial beta-2-agonist activity. Pharmacology. 1997;54:211-224.
22. Bonomi L, TomAazzoli L, Jaria D. An improved model of experimentally induced ocular hypertension in rabbits. Invest Ophthalmol Vis Sci. 1976;15:781-783.
23. Chen SJ, Huang YC, Wu BN, Chen IJ. Eugenolol: an eugenol-derived β-adrenoceptor blocker with partial β2-agonist and calcium mobilization inhibition associated vasorelaxant activities. Drug Develop Res. 1997;40:239-250.
24. Brown BL, Ekins RP, Albano JDM. Saturation assay for cyclic AMP using endogenous binding protein. Ad Cyclic Nucleotide Res. 1971;2:25-40.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall R. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275.
26. Yates SL, Fluhler EN, Lippiello PM. Advances in the use of the fluorescent probe fura-2 for the estimation of intrasynaptosomal calcium. J Neurosci Res. 1992;32:255-260.
27. Dhein S, Titzer S, Wallstein M, et al. Celiprolol exerts microvascular dilation by activation of β2-adrenoceptors. Arch Pharmacol. 1992;346:27-31.
28. Bohn M, Schulz C, Schwinger RHG, Eddmann E. Positive inotropic effects due to partial agonistic activity of the β-adrenoceptor antagonist celiprolol following amplification of cAMP formation in failing human myocardium. J Cardiovasc Pharmacol. 1992;20:479-489.
29. Tung LH, Jackman G, Campbell B, Louis S, Iakovidis D, Louis WJ. Partial agonist activity of celiprolol. J Cardiovasc Pharmacol. 1993;21:484-488.
30. Yablonski ME, Zimmerman TJ, Waltman SR, Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor of dynamics. Exp Eye Res. 1978;27:135-142.
31. Neufeld AH. Experimental studies on the mechanism of action of timolol. Surv Ophthalmol. 1979;23:363-370.
32. Schenker HI, Yablonski ME, Podos SM, Linder L. Fluorophotometric study of epinephrine and timolol in human subjects. Arch Ophthalmol. 1981;99:1212-1216.
33. Chiou GCY, Watanabe K, McLaughlin MA, Liu HK. Are β-adrenergic mechanisms involved in ocular hypotensive actions of adrenergic drugs? Ophthalmic Res. 1985;17:49-53.
34. Jin Y, Wilson S, Elko EE, Yorio T. Ocular hypotensive effects of medetomidine and its analogs. J Ocular Pharmacol. 1991;7:285-296.
35. Liu JHK, Galler J. In vivo cAMP level in rabbit iris-ciliary body after topical epinephrine treatment. Curr Eye Res. 1996;15:1025-1032.
36. Krieglstein GK, Langham ME, Leydhecker W. The peripheral and central actions of clonidine in normal and glaucomatous eyes. Invest Ophthalmol Vis Sci. 1978;17: 149-158.
37. Allen RC, Langham ME. The intraocular pressure response of conscious rabbits to clonidine. Invest Ophthalmol Vis Sci. 1976;15:815-823.
38. Langham ME. The intraocular pressure and the pupillary response of conscious rabbits to racemic erythro-α-methylnorepinephrine. Exp Eye Res. 1984;39:781-790.
39. Murray DL, Leopold IH. Alpha-adrenergic receptors in rabbit eyes. J Ocular Pharmacol. 1985;1:3-18.
40. Chiou GCY. Effects of α1 and α2 activation of adrenergic receptors on aqueous humor dynamics. Life Sci. 1983;32: 1699-1704.
41. Thorig L, Hoyng PF, Timmermans PBO, van Zwieten PA. M-7 lowers rabbit intraocular pressure. Ophthalmic Res. 1985;17:362-372.
42. Gherezghiher T, Koss MC. Ocular effects of adrenergic stereoisomers in the rabbit. J Ocular Pharmacol. 1985;1: 19-28.
43. Burke JA, Potter DE. Ocular effects of a relatively selective α2 agonist (UK-14,308-18) in cats, rabbits and monkeys. Curr Eye Res. 1986;5:665-676.
44. Chu TC, Wong W, Gluchowski C, Hughes BW, Potter DE. Rilmenicline-induced ocular hypotension: role of imidazoline1 and alpha2 receptors. Curr Eye Res. 1996;15:943-950.
45. Mittag TW, Tormay A. Adrenergic receptor subtypes in rabbit iris-ciliary body membranes: Classification by radioligand studies. Exp Eye Res. 1985;40:239-249.
46. Mittag TW, Tormay A, Severin C, Podos SM. Alpha-adrenergic antagonists: Correlation of the effect on intraocular pressure and on α2-adrenergic receptor binding specificity in the rabbit eye. Exp Eye Res. 1985;40:591-599.
47. 2+. Pharmacol Rev. 1988;40:87-119.
48. Kamm KE, Stull JT. Function of myosin and myosin light chain kinase in smooth muscle. Annu Rev Pharmacol Toxicol. 1985;25:593-620.
49. Limbird LE. Receptors linked to inhibition of adenylate cyclase: additional signaling mechanism. FASEB J. 1988; 2:2686-2695.
50. Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocular Pharmacol. 1993;9:373-384.
51. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Arch Ophthalmol. 1984;102:539-540.
52. Ober M, Scharrer A, David R, et al. Long-term ocular hypotensive effect of levobunolol results of a one-year study. Br J Ophthalmol. 1985;69:593-599.
53. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol. Arch Ophthalmol. 1986;104:46-48.
54. Nathanson JA. Stereospecificity of β adrenergic antagonist: R-enantiomers show increase selectivity for β2 receptors in ciliary process. J. Pharmacol Exp Ther. 1988; 245:94-101.
55. Horie T, Takahashi O. Comparison of ocular hypotensive effects of topical timolol and carteolol. Jap J Clin Ophthalmol. 1982;36:1065-1070.
56. Scoville B, Muller B, White BG, Krieglstein GK. A double-masked comparison of carteolol and timolol in ocular hypertension. Am J Ophthalmol 1988;105:150-154.
57. Hugues FC, Le Jeunne C, Munera Y. Systemic effects of topical antiglaucomatous drugs. Glaucoma. 1992;14:100-104.
58. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical carteolol 2% and timolol 0.5% in healthy volunteers. Br J Ophthalmol. 1988;72:101-103.